Evidence map›Paper›PMID 24758928›Full record

ArticleInternational journal of molecular sciences2014

Block of the mevalonate pathway triggers oxidative and inflammatory molecular mechanisms modulated by exogenous isoprenoid compounds.

Paola Maura Tricarico, Giulio Kleiner, Erica Valencic, Giuseppina Campisciano, Martina Girardelli, Sergio Crovella, Alessandra Knowles, Annalisa Marcuzzi

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Neuronal Dysfunction Associated with Cholesterol Deregulation.International journal of molecular sciences · 2018
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Lycopene Deficiency in Ageing and Cardiovascular Disease.Oxidative medicine and cellular longevity · 2016
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Paola Maura TricaricoDepartment of Medicine and Surgery and Health, University of Trieste, Piazzale Europa, 1, 34128 Trieste, Italy. tricaricopa@gmail.com.
Giulio KleinerInstitute for Maternal and Child Health IRCCS "Burlo Garofolo", 34137 Trieste, Italy. giulio.kleiner@burlo.trieste.it.
Erica ValencicInstitute for Maternal and Child Health IRCCS "Burlo Garofolo", 34137 Trieste, Italy. erica.valencic@gmail.com.
Giuseppina CampiscianoDepartment of Medicine and Surgery and Health, University of Trieste, Piazzale Europa, 1, 34128 Trieste, Italy. g.campisciano@gmail.com.
Martina GirardelliInstitute for Maternal and Child Health IRCCS "Burlo Garofolo", 34137 Trieste, Italy. martina.girardelli@burlo.trieste.it.
Sergio CrovellaDepartment of Medicine and Surgery and Health, University of Trieste, Piazzale Europa, 1, 34128 Trieste, Italy. sergio.crovella@burlo.trieste.it.
Alessandra KnowlesInstitute for Maternal and Child Health IRCCS "Burlo Garofolo", 34137 Trieste, Italy. alessandra.knowles@burlo.trieste.it.
Annalisa MarcuzziInstitute for Maternal and Child Health IRCCS "Burlo Garofolo", 34137 Trieste, Italy. annalisa.marcuzzi@burlo.trieste.it.
IRCCS Materno Infantile Burlo Garofolo · ITUniversity of Trieste · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deregulation of the mevalonate pathway is known to be involved in a number of diseases that exhibit a systemic inflammatory phenotype and often neurological involvements, as seen in patients suffering from a rare disease called mevalonate kinase deficiency (MKD). One of the molecular mechanisms underlying this pathology could depend on the shortage of isoprenoid compounds and the subsequent mitochondrial damage, leading to oxidative stress and pro-inflammatory cytokines' release. Moreover, it has been demonstrated that cellular death results from the balance between apoptosis and pyroptosis, both driven by mitochondrial damage and the molecular platform inflammasome. In order to rescue the deregulated pathway and decrease inflammatory markers, exogenous isoprenoid compounds were administered to a biochemical model of MKD obtained treating a murine monocytic cell line with a compound able to block the mevalonate pathway, plus an inflammatory stimulus. Our results show that isoprenoids acted in different ways, mainly increasing the expression of the evaluated markers [apoptosis, mitochondrial dysfunction, nucleotide-binding oligomerization-domain protein-like receptors 3 (NALP3), cytokines and nitric oxide (NO)]. Our findings confirm the hypothesis that inflammation is triggered, at least partially, by the shortage of isoprenoids. Moreover, although further studies are necessary, the achieved results suggest a possible role for exogenous isoprenoids in the treatment of MKD.

Indexed as

AnimalsApoptosisCarotenoidsCarrier ProteinsCell LineCytokinesDiterpenesHumansLycopeneMevalonate Kinase DeficiencyMevalonic AcidMiceMitochondriaNitric OxideNLR Family, Pyrin Domain-Containing 3 ProteinPhytolCarotenoidsCarrier ProteinsCytokinesDiterpenesgeranylgeraniolLycopeneMevalonic AcidNitric OxideNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mousePhytolTerpenes

Identifiers

PMID24758928
PMCPMC4013665
OpenAlexW1994126131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.